J.P. Morgan Maintains Their Hold Rating on Biogen (BIIB)

By Austin Angelo

In a report released yesterday, Cory Kasimov from J.P. Morgan maintained a Hold rating on Biogen (BIIBResearch Report). The company’s shares closed last Monday at $332.87.

According to TipRanks.com, Kasimov is a 4-star analyst with an average return of 6.8% and a 47.2% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Global Blood Therapeutics, and Alexion Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Biogen with a $316.53 average price target, implying a 10.8% upside from current levels. In a report issued on January 24, RBC Capital also maintained a Hold rating on the stock with a $285.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $374.99 and a one-year low of $215.78. Currently, Biogen has an average volume of 1.69M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.